M&A
confidence high
sentiment positive
materiality 0.75
Keenova Therapeutics plc: M&A transaction — Mallinckrodt completes Therakos sale, uses $887.6M net proceeds to cut net debt >60%
Keenova Therapeutics plc
- Closed Therakos divestiture for $925M base; net cash $887.6M after working capital adjustments.
- Mandatory debt prepayment on Dec 6: ~$474.1M term loans ($36.4M makewhole) and ~$301.4M notes ($27.3M makewhole).
- Total principal reduction ~$775.5M; net debt expected to fall more than 60%.
- Board adopted Second A&R Transaction Incentive Plan; bonus pool capped at 3% of transaction proceeds.
- PSU award agreements amended to convert to time-vested upon a Qualifying Significant Event.